Rapid deterioration of a patient with mucopolysaccharidosis type I during interruption of enzyme replacement therapy
- 29 June 2007
- journal article
- case report
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 143A (16) , 1925-1927
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 yearsMolecular Genetics and Metabolism, 2007
- Effect of discontinuing of laronidase in a patient with mucopolysaccharidosis type IJournal of Inherited Metabolic Disease, 2006
- Changes in hair morphology of mucopolysaccharidosis I patients treated with recombinant human α‐L‐iduronidase (laronidase, Aldurazyme)American Journal of Medical Genetics Part A, 2005
- The first 5years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis IExpert Opinion on Pharmacotherapy, 2005
- A general model for genetic regulation of turnover of glycosaminoglycans suggests a possible procedure for prediction of severity and clinical progress of mucopolysaccharidosesMedical Hypotheses, 2004
- Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-L-iduronidase (laronidase)The Journal of Pediatrics, 2004
- Cessation of enzyme replacement therapy in Gaucher diseaseGenetics in Medicine, 2002
- Enzyme-Replacement Therapy in Mucopolysaccharidosis INew England Journal of Medicine, 2001
- Changes in serum chitotriosidase activity with cessation of replacement enzyme (cerebrosidase) administration in Gaucher diseaseClinical Biochemistry, 2000
- A review and selection of simple laboratory methods used for the study of glycosaminoglycan excretion and the diagnosis of the mucopolysaccharidoses.Journal of Clinical Pathology, 1976